KR20210049855A - 위장관 장애들 및 천식의 치료에서 가복사돌의 사용 - Google Patents

위장관 장애들 및 천식의 치료에서 가복사돌의 사용 Download PDF

Info

Publication number
KR20210049855A
KR20210049855A KR1020217008438A KR20217008438A KR20210049855A KR 20210049855 A KR20210049855 A KR 20210049855A KR 1020217008438 A KR1020217008438 A KR 1020217008438A KR 20217008438 A KR20217008438 A KR 20217008438A KR 20210049855 A KR20210049855 A KR 20210049855A
Authority
KR
South Korea
Prior art keywords
patient
gaboxadol
hours
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217008438A
Other languages
English (en)
Korean (ko)
Inventor
매튜 듀링
Original Assignee
오비드 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오비드 테라퓨틱스 인크. filed Critical 오비드 테라퓨틱스 인크.
Publication of KR20210049855A publication Critical patent/KR20210049855A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217008438A 2018-08-22 2019-08-22 위장관 장애들 및 천식의 치료에서 가복사돌의 사용 Withdrawn KR20210049855A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721013P 2018-08-22 2018-08-22
US62/721,013 2018-08-22
PCT/US2019/047673 WO2020041574A1 (en) 2018-08-22 2019-08-22 Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma

Publications (1)

Publication Number Publication Date
KR20210049855A true KR20210049855A (ko) 2021-05-06

Family

ID=69591079

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008438A Withdrawn KR20210049855A (ko) 2018-08-22 2019-08-22 위장관 장애들 및 천식의 치료에서 가복사돌의 사용

Country Status (10)

Country Link
US (1) US20210177805A1 (cg-RX-API-DMAC7.html)
EP (1) EP3823619A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021535106A (cg-RX-API-DMAC7.html)
KR (1) KR20210049855A (cg-RX-API-DMAC7.html)
CN (1) CN112888437A (cg-RX-API-DMAC7.html)
AU (1) AU2019326539A1 (cg-RX-API-DMAC7.html)
CA (1) CA3110218A1 (cg-RX-API-DMAC7.html)
IL (1) IL280859A (cg-RX-API-DMAC7.html)
MX (1) MX2021002113A (cg-RX-API-DMAC7.html)
WO (1) WO2020041574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN115551514A (zh) * 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
AU4307800A (en) * 1999-04-30 2000-11-17 Merab Lomia New indication for use of antiepileptic agents and medicines
EP1863808A1 (en) * 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法

Also Published As

Publication number Publication date
CA3110218A1 (en) 2020-02-27
EP3823619A4 (en) 2021-11-17
IL280859A (en) 2021-04-29
WO2020041574A1 (en) 2020-02-27
EP3823619A1 (en) 2021-05-26
JP2021535106A (ja) 2021-12-16
US20210177805A1 (en) 2021-06-17
AU2019326539A1 (en) 2021-03-11
MX2021002113A (es) 2021-06-23
CN112888437A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
AU2011324137B2 (en) A combination composition
JP2023061957A (ja) 抑うつ障害の処置
CN111971035A (zh) 生酮饮食相容的芬氟拉明制剂
BR112021009365A2 (pt) formulação de glicocorticoide estável
WO2015089150A1 (en) Pharmaceutical formulations comprising vilazodone
Gracious et al. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series
CA2735834C (en) Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis
US20210177805A1 (en) Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
Othman et al. Combined ketamine and midazolam versus midazolam alone for initial treatment of pediatric generalized convulsive status epilepticus (Ket-Mid Study): a randomized controlled trial
Richardson et al. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents
CN119212693A (zh) 用于治疗肌萎缩性侧索硬化的牛磺酸二醇和苯丁酸钠的组合
US11090293B2 (en) Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
KR20210087952A (ko) 운동 장애들을 치료하기 위한 가복사돌, 가낙솔론 및 알로프레그나놀론의 사용
JP2025535313A (ja) 進行性家族性肝内胆汁うっ滞症を治療するための方法
CN105193712B (zh) 盐酸氨溴索注射液和制法
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
US20230285369A1 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
EA051220B1 (ru) Стабильный состав глюкокортикоидов
Buchman Bile Acid Sequestrants
WO2025137348A1 (en) Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile
WO2024173750A2 (en) Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent
CN115607556A (zh) 预防治疗哮喘或慢阻肺或过敏性疾病等的药物
HK40038071A (en) Ketogenic diet compatible fenfluramine formulation
Gracious et al. Weight Gain in Children and Adolescents: Case Series

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000